What is Proxima?
Proxima Bio is a prominent biotechnology firm dedicated to pioneering novel biological solutions and therapeutics. The company harnesses advanced life sciences research and biopharmaceutical development, employing cutting-edge biotechnology platforms, molecular biology, and drug discovery methodologies. Proxima Bio's core mission involves creating innovative treatments for a spectrum of diseases and medical conditions by translating biological insights into potential therapeutic interventions. Their research and development activities span drug discovery, therapeutic development, biologics research, and precision medicine approaches, aiming to address unmet medical needs across diverse therapeutic areas and improve patient outcomes.
How much funding has Proxima raised?
Proxima has raised a total of $80M across 1 funding round:
Seed
$80M
Seed (2026): $80M with participation from AIX Ventures, Magnetic Ventures, DCVC Management, and NVentures
Key Investors in Proxima
AIX Ventures
AIX Ventures is a venture capital firm specializing in seed-stage AI startups, aiming to partner with top AI practitioners to transform industries and build enduring companies.
Magnetic Ventures
Magnetic Ventures is a female-founded venture capital firm focused on early-stage founders leveraging AI, machine learning, and next-gen biotech for healthcare innovation, providing capital and hands-on support.
DCVC Management
DCVC is a deep tech venture capital firm that invests in entrepreneurs tackling global challenges, particularly through artificial intelligence in sectors like biotechnology and energy.
What's next for Proxima?
With this major strategic investment, Proxima is well-positioned to advance its pipeline of novel therapeutic candidates and biological solutions. The substantial capital infusion, contextualized as enterprise-level funding, suggests Proxima is likely in a growth or scaling phase, enabling further research and development, potential clinical trials, and expansion of its operational capabilities. This backing will likely fuel the company's efforts to translate its scientific discoveries into practical therapeutic solutions, potentially progressing toward commercialization and making a significant impact on human health.
See full Proxima company page
